MedTrace Logo

Organ Donation and Hydrocortisone Treatment

NCT00675272 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2015-04-06

No results posted yet for this study

Summary

Brain death patients who are selected for organ donation very often suffer from haemodynamic instability. To treat this, high amounts of vasoactive drugs(norepinephrine) may be needed to raise blood pressure. However,norepinephrine may have negative influence on several organs causing reduced blood flow ischemia. Our hypothesis is that hydrocortisone treatment may reduce the amount of vasoactive drugs needed to keep the blood pressure stable in patients selected for organ donation.

Conditions

  • Brain Death

Interventions

DRUG

hydrocortisone

hydrocortisone 50mg iv. every 6 hours

DRUG

sodium chloride

sodium chloride every 6 hours iv

Sponsors & Collaborators

  • Tampere University Hospital

    collaborator OTHER

  • Kuopio University Hospital

    lead OTHER

Principal Investigators

  • Stepani Bendel, MD · Kuopio University Hospital

  • Esko Ruokonen, MD, PhD · Kuopio University Hospital

  • Jyrki Tenhunen, MD, PhD · Tampere UH

  • Anna-Maija Antman, MD · Tampere UH

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2011-08-31
Completion
2011-12-31

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00675272 on ClinicalTrials.gov